αKlotho and Chronic Kidney Disease

J. A. Neyra, Ming C Hu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alpha-Klotho (αKlotho) protein is encoded by the gene, Klotho, and functions as a coreceptor for endocrine fibroblast growth factor-23. The extracellular domain of αKlotho is cleaved by secretases and released into the circulation where it is called soluble αKlotho. Soluble αKlotho in the circulation starts to decline in chronic kidney disease (CKD) stage 2 and urinary αKlotho in even earlier CKD stage 1. Therefore soluble αKlotho is an early and sensitive marker of decline in kidney function. Preclinical data from numerous animal experiments support αKlotho deficiency as a pathogenic factor for CKD progression and extrarenal CKD complications including cardiac and vascular disease, hyperparathyroidism, and disturbed mineral metabolism. αKlotho deficiency induces cell senescence and renders cells susceptible to apoptosis induced by a variety of cellular insults including oxidative stress. αKlotho deficiency also leads to defective autophagy and angiogenesis and promotes fibrosis in the kidney and heart. Most importantly, prevention of αKlotho decline, upregulation of endogenous αKlotho production, or direct supplementation of soluble αKlotho are all associated with attenuation of renal fibrosis, retardation of CKD progression, improvement of mineral metabolism, amelioration of cardiac function and morphometry, and alleviation of vascular calcification in CKD. Therefore in rodents, αKlotho is not only a diagnostic and prognostic marker for CKD but the enhancement of endogenous or supplement of exogenous αKlotho are promising therapeutic strategies to prevent, retard, and decrease the comorbidity burden of CKD.

Original languageEnglish (US)
JournalVitamins and Hormones
DOIs
StateAccepted/In press - 2016

Fingerprint

Chronic Renal Insufficiency
Kidney
Minerals
Disease Progression
Fibrosis
Vascular Calcification
Amyloid Precursor Protein Secretases
Hyperparathyroidism
Cell Aging
Autophagy
Vascular Diseases
Comorbidity
Rodentia
Heart Diseases
Oxidative Stress
Up-Regulation
Apoptosis
Genes

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • FGF23
  • Hyperphosphatemia
  • Klotho
  • Uremic cardiomyopathy
  • Vascular calcification

ASJC Scopus subject areas

  • Endocrinology
  • Physiology

Cite this

αKlotho and Chronic Kidney Disease. / Neyra, J. A.; Hu, Ming C.

In: Vitamins and Hormones, 2016.

Research output: Contribution to journalArticle

@article{7f8584ffad1d42c186bb288b5630174c,
title = "αKlotho and Chronic Kidney Disease",
abstract = "Alpha-Klotho (αKlotho) protein is encoded by the gene, Klotho, and functions as a coreceptor for endocrine fibroblast growth factor-23. The extracellular domain of αKlotho is cleaved by secretases and released into the circulation where it is called soluble αKlotho. Soluble αKlotho in the circulation starts to decline in chronic kidney disease (CKD) stage 2 and urinary αKlotho in even earlier CKD stage 1. Therefore soluble αKlotho is an early and sensitive marker of decline in kidney function. Preclinical data from numerous animal experiments support αKlotho deficiency as a pathogenic factor for CKD progression and extrarenal CKD complications including cardiac and vascular disease, hyperparathyroidism, and disturbed mineral metabolism. αKlotho deficiency induces cell senescence and renders cells susceptible to apoptosis induced by a variety of cellular insults including oxidative stress. αKlotho deficiency also leads to defective autophagy and angiogenesis and promotes fibrosis in the kidney and heart. Most importantly, prevention of αKlotho decline, upregulation of endogenous αKlotho production, or direct supplementation of soluble αKlotho are all associated with attenuation of renal fibrosis, retardation of CKD progression, improvement of mineral metabolism, amelioration of cardiac function and morphometry, and alleviation of vascular calcification in CKD. Therefore in rodents, αKlotho is not only a diagnostic and prognostic marker for CKD but the enhancement of endogenous or supplement of exogenous αKlotho are promising therapeutic strategies to prevent, retard, and decrease the comorbidity burden of CKD.",
keywords = "Cardiovascular disease, Chronic kidney disease, FGF23, Hyperphosphatemia, Klotho, Uremic cardiomyopathy, Vascular calcification",
author = "Neyra, {J. A.} and Hu, {Ming C}",
year = "2016",
doi = "10.1016/bs.vh.2016.02.007",
language = "English (US)",
journal = "Vitamins and Hormones",
issn = "0083-6729",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - αKlotho and Chronic Kidney Disease

AU - Neyra, J. A.

AU - Hu, Ming C

PY - 2016

Y1 - 2016

N2 - Alpha-Klotho (αKlotho) protein is encoded by the gene, Klotho, and functions as a coreceptor for endocrine fibroblast growth factor-23. The extracellular domain of αKlotho is cleaved by secretases and released into the circulation where it is called soluble αKlotho. Soluble αKlotho in the circulation starts to decline in chronic kidney disease (CKD) stage 2 and urinary αKlotho in even earlier CKD stage 1. Therefore soluble αKlotho is an early and sensitive marker of decline in kidney function. Preclinical data from numerous animal experiments support αKlotho deficiency as a pathogenic factor for CKD progression and extrarenal CKD complications including cardiac and vascular disease, hyperparathyroidism, and disturbed mineral metabolism. αKlotho deficiency induces cell senescence and renders cells susceptible to apoptosis induced by a variety of cellular insults including oxidative stress. αKlotho deficiency also leads to defective autophagy and angiogenesis and promotes fibrosis in the kidney and heart. Most importantly, prevention of αKlotho decline, upregulation of endogenous αKlotho production, or direct supplementation of soluble αKlotho are all associated with attenuation of renal fibrosis, retardation of CKD progression, improvement of mineral metabolism, amelioration of cardiac function and morphometry, and alleviation of vascular calcification in CKD. Therefore in rodents, αKlotho is not only a diagnostic and prognostic marker for CKD but the enhancement of endogenous or supplement of exogenous αKlotho are promising therapeutic strategies to prevent, retard, and decrease the comorbidity burden of CKD.

AB - Alpha-Klotho (αKlotho) protein is encoded by the gene, Klotho, and functions as a coreceptor for endocrine fibroblast growth factor-23. The extracellular domain of αKlotho is cleaved by secretases and released into the circulation where it is called soluble αKlotho. Soluble αKlotho in the circulation starts to decline in chronic kidney disease (CKD) stage 2 and urinary αKlotho in even earlier CKD stage 1. Therefore soluble αKlotho is an early and sensitive marker of decline in kidney function. Preclinical data from numerous animal experiments support αKlotho deficiency as a pathogenic factor for CKD progression and extrarenal CKD complications including cardiac and vascular disease, hyperparathyroidism, and disturbed mineral metabolism. αKlotho deficiency induces cell senescence and renders cells susceptible to apoptosis induced by a variety of cellular insults including oxidative stress. αKlotho deficiency also leads to defective autophagy and angiogenesis and promotes fibrosis in the kidney and heart. Most importantly, prevention of αKlotho decline, upregulation of endogenous αKlotho production, or direct supplementation of soluble αKlotho are all associated with attenuation of renal fibrosis, retardation of CKD progression, improvement of mineral metabolism, amelioration of cardiac function and morphometry, and alleviation of vascular calcification in CKD. Therefore in rodents, αKlotho is not only a diagnostic and prognostic marker for CKD but the enhancement of endogenous or supplement of exogenous αKlotho are promising therapeutic strategies to prevent, retard, and decrease the comorbidity burden of CKD.

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - FGF23

KW - Hyperphosphatemia

KW - Klotho

KW - Uremic cardiomyopathy

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=84961784144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961784144&partnerID=8YFLogxK

U2 - 10.1016/bs.vh.2016.02.007

DO - 10.1016/bs.vh.2016.02.007

M3 - Article

C2 - 27125746

AN - SCOPUS:84961784144

JO - Vitamins and Hormones

JF - Vitamins and Hormones

SN - 0083-6729

ER -